Literature DB >> 16823242

Decrease in amplitude of intracardiac ventricular electrogram and inappropriate therapy in patients with an implantable cardioverter defibrillator.

Hiroshi Watanabe1, Masaomi Chinushi, Daisuke Izumi, Akinori Sato, Shinsuke Okada, Kazuki Okamura, Satoru Komura, Yukio Hosaka, Hiroshi Furushima, Takashi Washizuka, Yoshifusa Aizawa.   

Abstract

Intracardiac electrograms are important for discrimination of tachyarrhythmia by implantable cardioverter defibrillators (ICD). A low R-wave can cause not only undersensing of ventricular tachyarrhythmia but also inappropriate discharges due to oversensing of unexpected signals because of its characteristic sensing algorithm. Therefore, this study aimed to investigate adverse events associated with R-wave amplitude. We included 115 consecutive patients followed-up over one year after implantation of a transvenous ICD system. The status of the ICD was checked every 3 months and intracardiac ventricular electrograms were analyzed. The decrease in R-wave amplitude was high in arrhythmogenic hypertrophy cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy (ARVC), and sarcoidosis. Low R-waves (< 5.0 mV) were observed in 13 patients at a follow-up of 15 +/- 16 months after implantation, and the mean R-wave was 3.0 +/- 0.8 mV. The frequency of low R-waves was high in ARVC (38%), sarcoidosis (33%), and dilated cardiomyopathy (17%). All of the dilated cardiomyopathy patients with low R-waves had severe left ventricular dysfunction. Inappropriate ICD therapy resulting from T-wave oversensing occurred in 7 patients and the R-wave was < 5.0 mV in 6 of the patients. The frequency of inappropriate therapy was high in patients with sarcoidosis. In 3 patients, inappropriate therapy caused ventricular tachyarrhythmia. In conclusion, decreases in R-wave amplitude occurred in some progressive cardiac disorders and caused inappropriate ICD discharges having arrhythmogenicity. Physicians should attempt to obtain a high R-wave amplitude during ICD implantation and careful follow-up is required, especially in patients with ARVC or sarcoidosis.

Entities:  

Mesh:

Year:  2006        PMID: 16823242     DOI: 10.1536/ihj.47.363

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  5 in total

1.  [Progression of heart failure during cardiac resynchronization therapy: what is the cause?].

Authors:  C W Israel; M Britten
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-03

2.  Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular cardiomyopathy: the course of electronic parameters, clinical features, and complications during long-term follow-up.

Authors:  Giacomo Mugnai; Ruggero Tomei; Clementina Dugo; Luca Tomasi; Giovanni Morani; Corrado Vassanelli
Journal:  J Interv Card Electrophysiol       Date:  2014-06-14       Impact factor: 1.900

3.  Transvenous or subcutaneous implantable cardioverter defibrillator: a review to aid decision-making.

Authors:  Milena Leo; Alexander J Sharp; Andre Briosa E Gala; Michael T B Pope; Timothy R Betts
Journal:  J Interv Card Electrophysiol       Date:  2022-07-14       Impact factor: 1.759

4.  An unusual resolution of T-wave oversensing in an implantable cardioverter defibrillator in a child with long QT syndrome.

Authors:  Mitchell I Cohen; Petros V Anagnostopoulos; Andrew Papez
Journal:  J Interv Card Electrophysiol       Date:  2009-01-16       Impact factor: 1.900

5.  Failure of ICD therapy in lethal arrhythmogenic right ventricular cardiomyopathy type 5 caused by the TMEM43 p.Ser358Leu mutation.

Authors:  Kasper Aalbæk Kjærgaard; Jens Kristensen; Henning Mølgaard; Jens Cosedis Nielsen; Henrik Kjærulf Jensen
Journal:  HeartRhythm Case Rep       Date:  2016-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.